FindTrial
Sign In

Role of CCL2 in Alcoholic Liver Diseases

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01128010
Enrollment
Unknown
Registered
2010-05-21
Start date
Unknown
Completion date
Unknown
Last updated
2010-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcoholic Liver Disease

Brief summary

Immune dysregulations, including cytokines and chemokines secretions occurs in alcoholic liver disease. Serum levels and liver expression of CCL2 are increased in patients with alcoholic hepatitis but the role of this chemokine in the pathogenesis of alcoholic liver disease is nevertheless unknown. The aim of the study is to analyze plasma level and liver expression of CCL2 and their relation with liver disease severity and inflammatory infiltrate in our cohort of alcoholic patients. We studied also the association between -2518 CCL2 polymorphism and the severity of alcoholic liver disease.

Interventions

None listed

Sponsors

Erasme University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

ALD patients Inclusion Criteria: * Excess alcohol intake * Abnormality of liver biopsy compatible with alcoholic aetiology * Caucasian ethnicity

Exclusion criteria

* Presence of any other chronic liver disease * co-infection with HIV Controls Inclusion criteria * Caucasian ethnicity * presence of a disease

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026